Drugs / CBD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06787118 | Dec 2025 → May 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06787118 ↗ |
| Route | Oral | “Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.” NCT06787118 ↗ |